About
Technology
Issues
FAQ
Links
Official Page
A phase 1 clinical trial of the sigma‐2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.